Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Evaluation of Res-O-Mat T3 micro test].
Yoshida S, Ozaki S, Tanaka S, Morio K, Shiomi F. Yoshida S, et al. Among authors: morio k. Horumon To Rinsho. 1977 Jul;25(7):791-6. Horumon To Rinsho. 1977. PMID: 908165 Japanese. No abstract available.
Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Masuda K, et al. Among authors: morio k. J Gastroenterol. 2018 Jan;53(1):161-162. doi: 10.1007/s00535-017-1352-z. J Gastroenterol. 2018. PMID: 28555325 No abstract available.
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K. Masuda K, et al. Among authors: morio k. J Gastroenterol. 2018 Jan;53(1):107-118. doi: 10.1007/s00535-017-1348-8. Epub 2017 May 4. J Gastroenterol. 2018. PMID: 28474222
Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury.
Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Nelson Hayes C, Tsugawa K, Yokozaki M, Chayama K. Morio K, et al. J Gastroenterol. 2017 Dec;52(12):1252-1257. doi: 10.1007/s00535-017-1345-y. Epub 2017 May 5. J Gastroenterol. 2017. PMID: 28477171
Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma.
Teraoka Y, Kimura T, Aikata H, Daijo K, Osawa M, Honda F, Nakamura Y, Morio K, Morio R, Hatooka M, Kobayashi T, Nakahara T, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Nagata Y, Chayama K. Teraoka Y, et al. Among authors: morio r, morio k. Hepatol Res. 2018 Feb;48(2):193-204. doi: 10.1111/hepr.12916. Epub 2017 Jun 24. Hepatol Res. 2018. PMID: 28544062
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Aikata H, Hayes CN, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K. Kan H, et al. Among authors: morio k. J Med Virol. 2017 Nov;89(11):1963-1972. doi: 10.1002/jmv.24885. Epub 2017 Jul 25. J Med Virol. 2017. PMID: 28657143
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K. Nagaoki Y, et al. Among authors: morio r, morio k. PLoS One. 2017 Aug 10;12(8):e0182710. doi: 10.1371/journal.pone.0182710. eCollection 2017. PLoS One. 2017. PMID: 28797106 Free PMC article.
Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis.
Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio K, Fujino H, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Nagaoki Y, et al. Among authors: morio k. Hepatol Res. 2018 Mar;48(4):264-274. doi: 10.1111/hepr.12996. Epub 2017 Dec 11. Hepatol Res. 2018. PMID: 29114970
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Kimura T, Nagata Y, Chayama K. Kodama K, et al. Among authors: morio k. Oncology. 2018;94(4):215-222. doi: 10.1159/000486483. Epub 2018 Feb 9. Oncology. 2018. PMID: 29428943
137 results